Microsoft moves into genetic-data

  • 5 June 2009

Microsoft Corporation has made a move into genetic data management, following its acquisition of Rosetta Inpharmatics LLC, a subsidiary of pharmaceutical firm Merck & Co.

The Rosetta technology will be used to add genetic and genomic data management abilities to Microsoft’s recently announced Amalga Life Sciences effort.

The agreement calls for Microsoft and Merck to collaborate on software to improve drug discovery and development. Financial details were not disclosed.

Link

Rosetta Inpharmatics LLC

Microsoft Amalga

 

Subscribe to our newsletter

Subscribe To Our Newsletter

Subscribe To Our Newsletter

Sign up

Related News

Life sciences plan aims to support a prevention-focused NHS

Life sciences plan aims to support a prevention-focused NHS

The government's Life Sciences Sector Plan aims to harness scientific innovation for economic growth and support a prevention-focused NHS.
Wes Streeting pledges to retain digital workforce amid NHS reforms

Wes Streeting pledges to retain digital workforce amid NHS reforms

Wes Streeting, health secretary, confirmed the government’s commitment to retaining the digital workforce amid the abolition of NHS England.  
NHS cyber security concerns raised about move to Windows 11

NHS cyber security concerns raised about move to Windows 11

Fears have been raised that the NHS could be hit by cyber security issues because organisations are not prepared to migrate to Windows 11.